20 June 2013
Keywords: Astellas, Qutenza, EU application, New Indication, Neuropathic pain
Article | 20 March 2012
The European Medicines Agency has been formally notified by Astellas Pharma Europe, a subsidiary of Japanese drug major Astellas (TYO: 4503) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
20 March 2012
21 March 2012
19 June 2013
© 2013 thepharmaletter.com